全球癌症诊断市场规模（按诊断类型、癌症类型、地区、范围和预测）

癌症诊断市场规模及预测

2024 年癌症诊断市场规模价值 1117 亿美元，预计到 2031 年将达到 1884.3 亿美元，在 2024-2031 年预测期内的复合年增长率为 6.77%。由于生物标记、影像等各个领域的技术进步不断进步，癌症患者数量不断增加，老年人口迅速增加，政府宣传活动不断开展，政府资金不断增加，全球癌症诊断市场预计将出现强劲增长。了这一目标。本报告对全球癌症诊断市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球癌症诊断市场

癌症是全球最常见的疾病之一。检测癌症的过程涉及使用专门用于诊断的某些技术和设备。透过正确且提前的诊断可以预防和控制癌症死亡。当患者出现癌症迹象时，癌症诊断即确认其患有癌症。早期诊断可以实现有效治疗并确保患者的生存机会。进行有效的诊断测试以确认或排除疾病的存在，监测疾病的进程，规划治疗并确定治疗的有效性。

在某些情况下，重新检测可能很重要，例如当患者的病情有所改善、所采集样本的品质较差或需要确认异常的检测结果时。癌症的诊断方法包括影像学检查、实验室检查（包括肿瘤标记）、肿瘤活检、内视镜检查、手术和基因检测。癌症诊断从体检开始。这使得可以检测癌症疾病常见的特定生物标记和蛋白质并进行诊断。检测癌症的另一个重要过程涉及使用专门用于诊断的某些技术和设备。

全球癌症诊断市场概览

全球癌症诊断市场的主要驱动力是创新产品的不断推出以及对各种疾病早期诊断的需求日益增长。此外，医疗保健和诊断领域的快速成长归功于技术先进的检测系统，这些系统更新了肿瘤筛检方法，能够提供可靠的结果。癌症发生率的不断上升刺激了用于监测疾病进展的筛检测试和诊断影像市场的发展，从而推动了市场的成长。

根据世界卫生组织 (WHO) 的数据，癌症是全球第二大死因，2018 年促使约 960 万人死亡。美国国家癌症研究所（NCI）确定，到2030年，每年新发生癌症病例数将达2,360万人。此外，癌症诊断领域的研究和开发也有望促进市场成长。例如，2020 年 1 月，葡萄牙波尔图大学的研究人员使用糖工程胃癌模型证明了针对 CD44v9（人类胃肠道癌细胞中表达的主要蛋白质剪接变体）的单克隆抗体的效力。糖基化在检测中的作用。

然而，不良的报销政策预计会阻碍市场成长。近年来，放射学领域在诊断影像设备方面取得了许多进展。大多数健康保险公司不会为使用电脑辅助检测 (CAD) 的程式提供报销。此外，癌症检测软体的高成本也有望阻碍市场成长。电脑辅助检测 (CAD) 软体的许可证有效期为一年，医院必须每年更新。儘管如此，寄生虫癌症活检平台的开发预计将为全球癌症诊断市场参与者提供丰厚的成长机会。此外，人工智慧在快速癌症检测中的应用也有望促进市场成长。

目录

第 1 章 全球癌症诊断市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球癌症诊断市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第 5 章全球癌症诊断市场按诊断类型划分

• 概述
• 切片和细胞学检测
• 诊断影像测试
• 内视镜检查
• 基因检测
• 其他

第6章 全球癌症诊断市场（以癌症类型）

• 概述
• 乳癌
• 白血病 胰臟癌
• 摄护腺癌
• 大肠癌和直肠癌
• 其他

第 7 章全球癌症诊断市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 8 章全球癌症诊断市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第9章 公司简介

• Illumina, Inc.
• Koninklijke Philips N.V.
• Agilent Technologies, Inc.
• General Electric Company
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company

第 10 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 11 章附录

• 相关研究

Cancer Diagnostics Market Size And Forecast

Cancer Diagnostics Market size was valued at USD 111.70 Billion in 2024 and is projected to reach USD 188.43 Billion by 2031 , growing at a CAGR of 6.77% during the forecast period 2024-2031. The global Cancer Diagnostics Market has witnessed strong growth owing to the increasing technological advancements in various fields such as biomarkers, imaging, etc., a growing number of cancer cases, rapid growth in the geriatric population, awareness actions by governments, and growing government funding. The Global Cancer Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cancer Diagnostics Market Definition

Cancer is one of the most popular comprehensive diseases in the world. The process of detecting cancer includes the usage of certain technology and devices specifically used in its diagnosis. Cancer deaths can be prevented and controlled due to proper and prior diagnosis. A cancer diagnosis is defined as the identification of cancer in patients who have developed the signs of the disease. Early diagnosis leads to effective treatment and secures the survival chances of the patient. Effective diagnostic testing is practiced to confirm or exclude the presence of disease, monitor the disease process, and plan for and decide the effectiveness of treatment.

In some cases, it is important to repeat testing when a person's condition has improved, if a sample received was not of good quality, or if an abnormal test result needs to be confirmed. Diagnostic ways for cancer may involve imaging, laboratory tests (including inspections for tumor markers), tumor biopsy, endoscopic examination, surgery, or genetic testing. Cancer diagnosis begins with a physical checkup. The detection of certain biomarkers and proteins that are common in cancer disorders thereby, results in the diagnosis process. Remarkable another process of detecting cancer includes the usage of certain technology and devices particularly used in its diagnosis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cancer Diagnostics Market Overview

The global Cancer Diagnostics Market is principally driven by the continual introduction of innovative products, coupled with a growing need for early diagnosis of various diseases. Also, the rapid growth of the healthcare and diagnostics sector can be assigned to the entrance of technologically advanced laboratory systems that have updated oncological screening in producing reliable results. The increasing incidence of cancer is triggering the market for these screening tests and imaging modalities used for observing disease progression, thereby driving the market growth.

According to the World Health Organization (WHO), cancer was the second-leading reason for death globally, subject to approximately 9.6 million deaths in 2018. The National Cancer Insititute (NCI) has determined the number of new cancer cases per year reaches 23.6 million by 2030. Moreover, R&D in cancer diagnostics is also anticipated to aid in the growth of the market. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported an assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 - a major protein splice variant is forms expressed in human gastrointestinal cancer cells-by monoclonal antibodies.

However, inadequate reimbursement policies are expected to hinder the growth of the market. There have been various advancements in radiology about imaging equipment in the recent past. Most medical insurance companies do not provide reimbursement for procedures utilizing Computer-aided Detection (CAD). Moreover, the high price of cancer detection software is also anticipated to hinder the growth of the market. Computer-aided detection (CAD) software is available with a one-year license and hospitals to have to renew it every year. Nonetheless, the development of biopsy platforms for associate animal cancers is expected to offer profitable growth opportunities for players in the global Cancer Diagnostics Market. Moreover, the use of AI in quick detection of cancer is also supposed to aid in the growth of the market.

Global Cancer Diagnostics Market Segmentation Analysis

The Global Cancer Diagnostics Market is segmented based on Diagnostic Type, Cancer Type, and Geography.

Cancer Diagnostics Market, By Diagnostic Type

• Biopsy and Cytology Tests
• Diagnostic Imaging Tests
• Endoscopy
• Genetic Tests
• Others
• Based on Diagnostic Type, the market is bifurcated into Biopsy and Cytology Tests, Diagnostic Imaging Tests, Endoscopy, Genetic Tests, and Others. The Diagnostic Imaging Tests segment has dominated the major market share and is estimated to witness the highest CAGR for the forecast period. Imaging modalities such as Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) are fast, non-invasive, and pain-free diagnostic explications. These imaging modalities are applied as supportive tests along with other laboratory and genetic tests to discover the location and sharpness of the condition in diagnosing a different type of cancer, thereby helping in the choice of a suitable treatment regimen

Cancer Diagnostics Market, By Cancer Type

• Breast Cancer
• Leukemia
• Pancreatic Cancer
• Prostate Cancer
• Colon and Rectal Cancer
• Others

Based on Cancer Type, the market is bifurcated into Breast Cancer, Leukemia, Pancreatic Cancer, Prostate Cancer, Colon and Rectal Cancer, and Others. The Breast Cancer segment is estimated to witness the highest CAGR for the forecast period. The significant causes leading to an upsurge in breast cancer prevalence and percentage rates are hormone replacement therapy, obesity, reduced childbearing and age-related dangers. Transforming lifestyles and increased drink consumption can be directly linked with breast cancer prevalence as well as measure, as it results in an increase in estrogen levels in the body.

Cancer Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world.

Based on Regional Analysis, the Global Cancer Diagnostics Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominated the market by capturing the largest revenue share and is expected to continue its lead throughout the forecast period owing to factors such as more prominent funding available for research and development plans and the huge adoption of advanced technologies. The presence of various biotechnology as well as medical device companies in this region is also one of the principal factors driving the diagnostics sector in the region. The Asia Pacific is also expected to grow at a significant rate due to the availability of skilled technicians at a comparatively lower price and a defined regulatory framework favoring advanced product approvals.

Key Players

• The "Global Cancer Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Illumina, Inc., Koninklijke Philips N.V., Agilent Technologies, Inc., General Electric Company, F. Hoffmann-La Roche Ltd, and Becton, Dickinson, and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• Product Launches and Merchandise Expansions
• In Nov 2021, Becton, Dickinson, and Co., a key medical devices company, launched a machine-controlled high-throughput diagnostic system for cervical cancer screening, dubbed the Bachelor of Divinity COR PX/GX System.
• In August 2021, the system Approved by the U.S. Food and Drug Administration has been designed to be used in centralized labs and might handle the high-volume process with exaggerated potency.
• Partnerships, Collaborations, and Agreements
• In 2020, GE aid entered a partnership with GenesisCare to boost patient outcomes for the 2 biggest health burdens globally, cancer and cardiovascular disease. GE aid can give CT, MRI, PET/CT, SPECT, digital diagnostic techniques, and ultrasound instrumentation to GenesisCare's 440+ cancer and upset treatment centers across Australia, the US, the UK, and Spain.
• In 2020, Roche medicine entered a partnership with Illumina to supply broad access to clinical medical specialty next-generation sequencing.
• Mergers and Acquisition
• In March 2021, Agilent Technologies INC. nonheritable Resolution natural science, to bolster its headship position in cancer medicine.
• In September 2020, Illumina, Inc.'s nonheritable goblet launched a brand-new section of cancer diagnosing. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosing tests with the possibility to observe a lot of cancers earlier and alter higher outcomes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CANCER DIAGNOSTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CANCER DIAGNOSTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

• 5.1 Overview
• 5.2 Biopsy and Cytology Tests
• 5.3 Diagnostic Imaging Tests
• 5.4 Endoscopy
• 5.5 Genetic Tests
• 5.6 Others

6 GLOBAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

• 6.1 Overview
• 6.2 Breast Cancer
• 6.3 Leukemia
• 6.4 Pancreatic Cancer
• 6.5 Prostate Cancer
• 6.6 Colon and Rectal Cancer
• 6.7 Others

7 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Illumina, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Koninklijke Philips N.V.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Agilent Technologies, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 General Electric Company
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 F. Hoffmann-La Roche Ltd.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Becton, Dickinson and Company
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research